Novo Nordisk reaches for billion dollars: expansion in the USA and Europe!

Novo Nordisk reaches for billion dollars: expansion in the USA and Europe!

The Danish pharmaceutical company Novo Nordisk is facing a huge growth step: with one billion -off deal, the group is planning to take over three filling systems in the USA, Italy and Belgium. This expansion is crucial in order to meet the rapidly increasing demand for its popular delegates, especially the products Ozempic and Wegovy. The company announces that the deal has already been approved by the responsible authorities and is expected to be completed in the coming days. The background is the fact that Novo Nordisk can currently hardly keep up with the production of his medication, since interest increases in both diabetics and people with overweight people, such as the Wiener Zeitung reported.

strategic steps and concerns

The expansion of the production capacities was announced in February, with Novo Holdings, the main part of Novo Nordisk, will take over the US company Catalent. This is one of the leading providers in the pharmaceutical industry that fills numerous medication for other companies. The value of the acquisition is more than $ 11 billion and could have a significant impact on the market. However, industry observers report that there are concerns on the part of the competitor Eli Lilly as well as from consumer protectors and unions. These warnings indicate that the deal could possibly have competition law and social implications, as the emphasizes.